hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Hyperparathyroidism Signs and Symptoms

Definition

  • Caused by excessive parathyroid hormone (PTH) production

Signs and Symptoms

  • Usually related to elevated levels of PTH & serum calcium
  • Classic signs & symptoms include bone disease, kidney stones & hypercalcinosis
  • Constipation
  • Hypertension
  • Muscle weakness
  • Nausea
  • Polydipsia
  • Polyuria
  • Psychiatric symptoms (depression, anxiety, etc)
  • Significant loss of appetite

Epdemiology

  • Primary hyperparathyroidism is the most common endocrine cause of hypercalcemia in ambulatory patients
  • Occurs more in women than in men aged >50 years old
  • 85-95% of primary hyperparathyroidism is due to adenoma
  • Sporadically arising solitary parathyroid adenoma is the most common primary hyperparathyroidism (PHPT)
  • Familial syndromes - 2nd most common cause of PHPT
  • Renal failure - most common cause of secondary hyperparathyroidism
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.